Close

Search

Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
SPECIAL ANNOUNCEMENT
2016 Photonics Buyers' Guide Clearance! – Use Coupon Code FC16 to save 60%!
share
Email Facebook Twitter Google+ LinkedIn Comments

Spectranetics PELA Study Extended

Photonics.com
Jan 2002
COLORADO SPRINGS, Jan. 16 -- The Spectranetics Corp. said it has FDA approval to continue its peripheral excimer laser angioplasty (PELA) study, without the need to randomize patients. The study extension, PELA III, allows the excimer laser to be used to treat total occlusions at least 10 cm long of the main thigh artery for 120 additional patients at 21 sites. Patients will be enrolled in PELA III during the follow-up and approval phases of the PELA trial, which completed randomized patient enrollment in November, is on track to receive FDA approval in 2003, Spectranetics said.


Comments
Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2016 Photonics Media
x We deliver – right to your inbox. Subscribe FREE to our newsletters.